by The global Postpartum Depression Drug Market is estimated to be valued at US$ 6.650 Bn in 2022 and is expected to exhibit a CAGR of 30.25% over the forecast period 2022-2029.
Market Overview:
Postpartum depression (PPD) is a mood disorder that can affect women after childbirth. It causes feelings of extreme sadness, anxiety, and exhaustion that may make it difficult for new mothers to complete daily care activities for themselves or for their baby. Postpartum depression drugs help relieve symptoms of PPD and help mothers feel better. These drugs include antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). The need for postpartum depression drugs has increased significantly in recent years as more awareness has been created about this condition and more women seek treatment.
Market Key Trends:
One of the major trends in the postpartum depression drug market is the rise in new product approvals and launches by key players. Several new drugs have been approved in recent years for treatment of PPD. For instance, in 2019, the FDA approved brexanolone, sold under the brand name Zulresso, as the first drug specifically for treatment of postpartum depression. Additionally, major players are focusing on developing drugs with improved safety profiles and fewer side effects to expand treatment options for new mothers. Population-based screening programs for early detection of PPD cases have also increased, thereby fuelling demand for effective drug therapies in the market.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the Postpartum Depression Drug Market is moderate. Developing new drugs requires high capital investment and getting regulatory approvals is a long process.
Bargaining power of buyers: The bargaining power of buyers is high as there are several available treatment options for buyers to choose from. Buyers can negotiate on price if a new drug enters the market.
Bargaining power of suppliers: The bargaining power of suppliers is low as there are many suppliers for raw materials. Suppliers do not have control over pricing.
Threat of new substitutes: The threat of new substitutes is high as alternative treatment options like therapy and lifestyle changes can be adopted. Moreover, generic versions pose a threat once patents of branded drugs expire.
Competitive rivalry: The competitive rivalry in the postpartum depression drug market is high due to the presence of many established companies. Companies compete based on product differentiation, pricing strategies and promotional activities.
Key Takeaways
The global postpartum depression drug market is expected to witness high growth, exhibiting CAGR of 30.25% over the forecast period, due to increasing awareness about postpartum depression and its treatment options.
Regional analysis:
North America dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to growing awareness about mental health in the region. However, Asia Pacific is expected to witness the fastest growth due to improving healthcare infrastructure and rising disposable incomes in the region.
Key Players:
Key players operating in the postpartum depression drug market are Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd. Sage Therapeutics’ lead drug Zulresso was the first pharmacological treatment approved by the FDA for postpartum depression in 2019.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
